Strategies for Meeting NDA Submission Timelines

This case study outlines the strategies employed by a midsize pharmaceutical company in collaboration with Worldwide Clinical Trials to meet the FDA's unexpected supplemental study requests for a new oncology drug. The study was conducted at Worldwide’s Clinical Pharmacology Unit in San Antonio, Texas, and involved five last-minute studies, including assessments of drug-drug interactions and the effects of a high-fat diet on pharmacokinetics. The document details the challenges faced, including tight timelines and logistical complexities, and emphasizes the importance of early regulatory engagement and proactive communication with the FDA. It describes how Worldwide's rapid start-up processes and multi-site network facilitated the completion of the studies within eight months, allowing the sponsor to submit the New Drug Application (NDA) on schedule. The successful execution of these studies led to FDA approval, enabling the drug to reach the market for cancer patients.